Supreme Court rejects Allergan patent appeal over Sanctura
(Reuters) - The U.S. Supreme Court rejected on Monday Allergan Inc's appeal of a ruling that favored generic drugmaker Watson Pharmaceuticals Inc over patents related to the treatment of an overactive bladder.
Allergan was challenging a June decision by the U.S. Federal Circuit Court of Appeals that its patents related to Sanctura XR were invalid because the treatment was "obvious," meaning it was highly likely to succeed based on information already known.
(Reporting By Terry Baynes and Jon Stempel in New York; Editing by Howard Goller and Gerald E. McCormick)
- Cortege departs to take Mandela's body to lie in state |
- U.S. Mega Millions lottery up to $344 million, fourth biggest in its history
- Uruguay becomes first country to legalize marijuana trade
- UPDATE 1-U.S. Mega Millions lottery up to $344 million, fourth biggest in its history
- Ukrainian riot police clash with protesters in Kiev square
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more